Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic
Executive Summary
The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.
You may also be interested in...
San Antonio Breast Cancer Symposium: New Diagnostics From Myriad, Lumicell, Agendia
Myriad Genetics, Lumicell, and Agendia were among the companies with diagnostic technologies featured in the scientific presentations at the recent San Antonio Breast Cancer Symposium. New trials show that Myriad's EndoPredict can help identify patients who should not have preoperative chemotherapy. New Phase II data support Lumicell's LUM system for guiding excision of residual tumor and preventing cancer recurrence. Agendia's MammaPrint test proved cost-effective in the MINDACT trial.
Minute Insight: Medtronic Brings Hugo RAS To Canada
Health Canada has licensed Hugo for urologic and gynecologic laparoscopic surgical procedures.
Digital Health Roundup: A Season For Interviews, New Frontiers, AI, Cybersecurity
In this roundup feature focusing on developments in digital health, Medtech Insight highlights interviews with Medtronic, Abbott and Congenica, partnerships and launches, and AI and cybersecurity announcements from November.